AAML1522: A Phase II, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid) in Pediatric Subjects From 1 to 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia

Protocol: 
AAAP9858
Phase: 
II

AAML1522: A Phase II, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid) in Pediatric Subjects From 1 to 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia

Are you Eligible? (Inclusion Criteria)

-Subjects must be at least 1 year and up to 18 years of age at the time of study
entry.
-Subject must have Relapsed or Refractory Acute Myeloid Leukemia (rrAML) after
at least 2 prior treatment attempts.
-Subject must be willing and able to adhere to the study visit schedule and
other protocol requirements.
-Patients must also meet all eligibility criteria as outlined in the study
protocol.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States